As ASCO 2025 commenced in Chicago on Friday 30th May, pharmaphorum headed over to the Windy City’s Willis Tower for Johnson & ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as ...

The most successful pharma sales teams will be those that define and service customers in new ways. Those who are the most responsive and relevant to today's customers and influencers will reap ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement in overall survival.

Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines. Headquartered in Basel ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after getting confirmation it will be covered by the NHS in all four nations.

COP27 is in full swing and world leaders are contending with the fact that we will likely not meet the Paris Agreement’s 1.5°C target. The reality is that we will need to focus on limiting a ...

Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in Europe for ...